Market Overview

Allergan to Acquire MAP Pharmaceuticals for $25.00/Share

Related AGN
#PreMarket Primer: Friday, November 21: Immigration Reform Could Have Lasting Impact In More Ways Than One
Can The Uptrend Continue For Allergan?
Deal Frenzy: 2014 Sees Record M&A Volume (Fox Business)

Allergan (NYSE: AGN) and MAP Pharmaceuticals (NASDAQ: MAPP)
today jointly announced that they have entered into a definitive merger
agreement whereby Allergan will acquire 100% of the shares of MAP
Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is
a biopharmaceutical company focused on developing and commercializing
new therapies in Neurology, including LEVADEX®, an orally inhaled drug
for the potential acute treatment of migraine in adults. LEVADEX® is
currently under review with the U.S. Food and Drug Administration (FDA).

The transaction, which has been unanimously approved by the boards of
directors of both companies, will be accomplished pursuant to a cash
tender offer followed by a second step merger. The per share cash

See full press release

Posted-In: News Guidance Management M&A

 

Related Articles (MAPP + AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters